Hybridan Research: Sareum Holdings plc: Upping the Pace
There is a loss before tax reduced to £1.33m, compared to a loss of £2.5m (H123 to end Dec 2023) which included Phase 1a clinical trial costs.
180 Views
Sareum Holdings — New fund-raise and licence signal active 2025
Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had...
310 Views
Sareum Holdings PLC - Opportunistic Opportunity 13 March 2025
Sareum has now acquired this licence, and the economic terms have been renegotiated, so Sareum will receive a net 63.5% of all future revenues, up...
291 Views
Hybridan Small Cap Feast: 26/03/2025
Since the period end, its secured the Global Economic Forum in Davos which is expected to open new opportunities in the financial and professional...
210 Views
No more insights